Roche to pay $42 million to Ascidian to make RNA exon editing drugs
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Drugs
Health
Pharma
Drugs
Health
Pharma
US drug regulator approves two treatments for sickle cell disease
HQ Team December 8, 2023: The USFDA has approved two treatments for sickle cell disease, one of them the first in the US.
Drugs
Health
Pharma
Cambridge Univ, AstraZeneca, MRC to set up genomics laboratory
HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.
Drugs
Health
Pharma
AstraZeneca inks $245 million deal with Cellectis for rare diseases
HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.
Drugs
Health
Pharma
Biomedical engineers create ML model to turn genes on and off
HQ Team August 14, 2023: Biomedical engineers at Johns Hopkins have developed a machine-learning model, which can turn on genes —an innovation which.
Drugs
Health
Pharma
Gene editing kills female mosquitoes that spread malaria
HQ Team July 10, 2023: US researchers have genetically edited mosquitoes to kill females of the species responsible for the spread of malaria..
Drugs
Medical
Pharma
‘Love hormone’ Oxytocin breaks a three-decade-old perception
The receptor of Oxytocin, a hormone considered essential to forming social bonds, may not play the role that scientists have assigned it for.